BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|May 1, 2008
- Volume 0 0
productHOTLINE
Advertisement
Articles in this issue
over 18 years ago
advertiserINDEXover 18 years ago
Motion Sickness: Calming the Waves of Upsetover 18 years ago
pharmacy Pet Peevesover 18 years ago
recruitment/RESOURCESover 18 years ago
canyouREADtheseRxs?over 18 years ago
Case Studiesover 18 years ago
DIABETESWATCHover 18 years ago
CHOLESTEROLWATCHover 18 years ago
compoundingHOTLINEover 18 years ago
ARTHRITISWATCHAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement